From Policy to Proof: How DSCSA Is Becoming Operational [HDA 2026 Insights Part 1 of 2]

The Healthcare Distribution Alliance (HDA) Distribution Management Conference in Austin made one thing clear: DSCSA has moved out of planning mode and into day-to-day execution.

Across sessions and regulator updates, a consistent message emerged. Compliance, data quality, and operations can no longer be managed separately. They have to work together—and they have to work in real time.

FDA: Inspections Are Now the Norm

FDA made it clear that DSCSA is no longer a special topic. It is part of routine oversight.

Even when inspections begin with manufacturing concerns, they now expand into supply chain controls. That includes authorized trading partner (ATP) verification, suspect product handling, and companies demonstrating what their procedures say they do.

“For-cause” inspections remain a key tool. But what’s changed is that DSCSA expectations are now showing up everywhere.

One example highlighted this shift. FDA inspected a medical spa acting as a dispenser and found gaps in ATP documentation, inventory mismatches, and a product without a proper identifier.

Takeaway: DSCSA expectations apply across the entire ecosystem—not just traditional pharmacies.

From Paper Compliance to Proof

Both FDA and state boards emphasized a clear shift. It’s no longer enough to have policies written down. Regulators want to see that those policies are working in practice.

That means clear SOPs, defined roles, and staff who can execute processes in real time. It also means having traceable workflows for ATP verification, transaction records, and suspect product investigations.

Compliance today is about evidence, not documentation.

State Boards Are Stepping In

State boards of pharmacy are also increasing their focus on DSCSA, though the pace varies.

Some are incorporating DSCSA into routine inspections. Others are educating licensees during site visits. Many are placing more emphasis on how quickly organizations can respond to trace requests.

That last point matters. When regulators ask for information, speed and accuracy are critical—not just for compliance, but for public safety.

Small Dispensers: A Growing Risk Area

One of the biggest challenges discussed at HDA was the readiness of small dispensers.

Many lack the IT infrastructure, staffing, or process maturity of larger organizations. As a result, they struggle with connectivity, data standards, and consistent execution.

These issues don’t stay isolated. They show up across the supply chain as exceptions, delays, and verification problems.

For manufacturers and wholesalers, supporting smaller partners is now essential to keeping product moving.

LSPedia’s Pharmacy Pro is designed specifically for dispensers and medspas, helping simplify DSCSA compliance, improve data accuracy, and make it easier to meet evolving regulatory expectations, without adding heavy IT burden.

Exceptions Won’t Save You

There was also strong messaging around waivers, exceptions, and exemptions (WEEs). The FDA made it clear these are narrow tools, not a long-term strategy.

Requests often fail when they are too broad, lack evidence, or show weak internal controls. A lack of effort to build electronic connections can also work against approval.

Successful requests are tightly scoped, well-supported, and include a clear path back to compliance.

NDC12: Start Earlier Than You Think

The shift to a 12-digit National Drug Code (NDC12) will impact nearly every system.

It touches master data, pricing, returns, and pharmacy-level scanning. While the timeline may seem long, speakers warned against repeating DSCSA delays.

Organizations that start early will be better positioned to adapt.

Bottom Line

The biggest takeaway from HDA isn’t a single regulation. It’s a shift in expectations.

Organizations need to treat data as infrastructure, invest in systems and people, and strengthen how they manage trading partners and traceability. Engaging partners across the supply chain—especially smaller ones—will also be critical.

The next phase of regulation will reward companies that can prove what they do—not just describe it.

In Part 2 of our HDA 2026 Insights, we’ll look at how drug pricing pressures are colliding with operational demands and how serialization data can help organizations manage complexity and unlock real ROI.

‍